Company profile
Celldex Therapeutics, Inc.
NASDAQ:CLDXBiotechnology: In Vitro & In Vivo Diagnostic Substances
Drug pipeline (10)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| CDX-301 | phase2 | — | 4 | completed, terminated |
| CDX-3379 | phase2 | — | 1 | terminated |
| GLEMBATUMUMAB VEDOTIN | phase2 | — | 2 | no active trials |
| RASDEGAFUSP ALFA | phase1_2 | — | 2 | completed, terminated |
| Barzolvolimab | phase1 | — | 5 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (43)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02335918 | phase1_2 | completed | 2015-01-01 | 2018-12-12 | Celldex Therapeutics | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors |
| NCT02837991 | phase1 | terminated | 2016-06-01 | 2018-11-16 | Celldex Therapeutics | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma |
| NCT04146129 | phase1 | completed | 2019-10-29 | 2020-04-06 | Celldex Therapeutics | A Phase 1 Study of CDX-0159 |
| NCT05031624 | phase1 | completed | 2021-08-30 | 2022-01-14 | Celldex Therapeutics | A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects |
| NCT02014909 | phase1 | completed | 2014-01-01 | 2017-05-25 | Celldex Therapeutics | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors |
FDA applications (0)
No records yet.